Streetbeat News

Stock Prices

EYE

National Vision's shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided positive guidance for the future.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:54 pm

NERV

Minerva Neurosciences Inc (NASDAQ:NERV) faces a regulatory setback as the FDA issues a Complete Response Letter (CRL) for its schizophrenia treatment candidate, roluperidone, citing clinical deficiencies and requesting additional data. The FDA's concerns include insufficient evidence of effectiveness from a single study, lack of data on concomitant antipsychotic administration, and inadequate safety database. Minerva must submit further studies to address these issues. NERV shares plummeted 62.1% to $2.55 in premarket trading.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 5:53 pm

LFWD

ReWalk Robotics Ltd. (NASDAQ:LFWD), also known as Lifeward, reported Q4 earnings with an EPS of $(0.05), missing the consensus of $(0.10). Revenue was $6.9 million, below the $7.22 million estimate. The adjusted gross margin decreased to 47% from 52.8% a year ago, with total operating expenses rising to $8.6 million from $5.7 million. For FY24, Lifeward expects revenue between $28 million and $32 million, with a non-GAAP gross margin in the high 40%s. LFWD shares dropped 3.89% to $0.8911.

Portfolio Pulse from Nabaparna Bhattacharya

February 27, 2024 | 5:53 pm

BTCUSD

Pseudonymous trader Capo of Crypto, known for bearish Bitcoin predictions, recently forecasted a Bitcoin drop to $45,000, just before Bitcoin surged 12% past $53,000 resistance. Despite Capo's history of bearish calls, including a notable prediction of Bitcoin hitting $12,000, the cryptocurrency community remains entertained, with some viewing his predictions as inversely predictive. Technical analysts remain bullish on Bitcoin, with expectations of further gains.

Portfolio Pulse from Ivan Crnogatić

February 27, 2024 | 5:50 pm

VERV

Verve Therapeutics shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:46 pm

BGNE

BeiGene's stock price increased following the announcement that the FDA has accepted a Biologics License Application for TEVIMBRA.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:46 pm

SE

Market whales have shown a mixed sentiment on Sea (NYSE:SE) with a bearish lean, as evidenced by recent options trading activity. Benzinga's options scanner revealed 19 unusual trades, with a split sentiment of 42% bullish and 57% bearish. The trades focus on a price band between $22.5 and $100.0 for Sea. The largest trades include both calls and puts with varying sentiments and strike prices. Sea, known for its e-commerce platform Shopee and gaming business Garena, has seen its stock price increase by 0.9% to $45.77. An analyst from Citigroup has upgraded Sea to Buy with a target price of $50.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 5:46 pm

MRVL

Deep-pocketed investors have shown a bullish trend in options trading for Marvell Tech (NASDAQ:MRVL), with a significant move detected by Benzinga's options scanner. The activity includes 24 extraordinary options activities, with a bullish sentiment from 58% of investors. The focus is on a price band between $55.0 and $90.0. The volume of MRVL is up 1.43% at $69.6, with RSI indicators suggesting it may be approaching overbought. An analyst from UBS maintains a Buy rating with a target price of $83.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 5:45 pm

JANX

Janux Therapeutics Inc (NASDAQ:JANX) released promising data for its cancer treatments, JANX007 and JANX008, showing significant efficacy and safety. JANX007, targeting metastatic castration-resistant prostate cancer, demonstrated high rates of PSA declines and favorable safety profiles in a Phase 1a trial. JANX008, aimed at various solid tumors, also showed encouraging clinical activity and safety. Following these updates, Janux's stock surged 186.5% to $43.26, yet William Blair considers it undervalued, highlighting the potential of Janux's TRACTr platform.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 5:41 pm

CRD

EHTH

RELI

TRUP

Insurance stocks showed notable movements in Tuesday's intraday session. Gainers included Reliance Global Group, Trupanion, Hippo Holdings, Erie Indemnity, Lemonade, and Root, with increases ranging from 6.76% to 15.39%. Losers were eHealth, Crawford (with two different stock symbols), Oxbridge Re Holdings, Waterdrop, and Maiden Holdings, with declines between 2.26% and 9.21%. Notably, several companies released their Q4 earnings reports, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 5:40 pm